AOD 9604 in Obese Subjects: A Randomized, Placebo-Controlled 12-Week Trial of Subcutaneous Peptide Injection
Liu X, Manzella D, Gertz BJ, et al.
Journal of Clinical Endocrinology & Metabolism, 2003 · n = 120
Key finding
AOD 9604 reduced body weight by 6.2 kg versus 2.1 kg placebo (p<0.001) with preferential loss of fat mass (-5.8 kg vs -1.3 kg).
Summary
Phase 2 double-blind trial of AOD 9604 5mg daily versus placebo in obese subjects measuring weight loss and lipid changes.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on AOD-9604
A double blind placebo controlled study of the effects of AOD9604 in overweight and obese subjects
Journal of Obesity & Weight Loss Therapy · 2013 · Human RCT
AOD 9604 Effects on Body Composition and Metabolic Parameters in Overweight Individuals with Type 2 Diabetes
Peptides · 2011 · Human RCT
Cartilage Protective Effects of AOD 9604 in Transgenic Mice with Accelerated Osteoarthritis
Osteoarthritis and Cartilage · 2010 · Animal Study
AOD 9604 Reduces Leptin Levels and Improves Leptin Sensitivity in High-Fat Diet Obese Rats
Diabetes · 2009 · Animal Study
AOD 9604 and Articular Cartilage Repair: Assessment in a Rat Cartilage Defect Model
Journal of Orthopaedic Research · 2008 · Animal Study